Fidelity Investments’s Pacer BioThreat Strategy ETF VIRS Stock Holding History

Fidelity Investments’s Portfolio VIRS Stock Details VIRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$28	–	5584
2022 Q4	$28	Buy	+1	New	+$28	﹤0.01%	5044
2022 Q3	–	Sell	-1	Closed	–	–	5500
2022 Q2	$0	Buy	+1	New	+$28	﹤0.01%	5599
2021 Q3	–	Sell	-1	Closed	–	–	5162
2021 Q2	$0	Buy	+1	New	+$30	﹤0.01%	5007

Other funds holding VIRS

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments's VIRS Position: Q1 2023 in Review

Fidelity Investments sold out of Pacer BioThreat Strategy ETF (VIRS) in Q1 2023, closing a stake of 1 share — an estimated $28 sold.

Fidelity Investments first reported a position in VIRS in Q2 2021 and held it in 3 quarters. The position peaked at $28 in Q4 2022. 4 funds tracked by Wall St. Rank hold VIRS as of Q1 2023.

Fidelity Investments reported no remaining Pacer BioThreat Strategy ETF position as of Q1 2023 after selling out during the quarter.
Fidelity Investments sold 1 Pacer BioThreat Strategy ETF share in Q1 2023, an estimated $28.
Fidelity Investments first reported a position in Pacer BioThreat Strategy ETF in Q2 2021 and held it in 3 quarters.
Fidelity Investments's Pacer BioThreat Strategy ETF position peaked at $28 in Q4 2022.
4 funds tracked by Wall St. Rank held Pacer BioThreat Strategy ETF as of Q1 2023.

Based on Fidelity Investments's 13F filing for Q1 2023, filed 11 May 2023.